Core Viewpoint - The company plans to change the purpose of repurchased shares from "employee stock ownership plan" to "reduce registered capital" and will seek shareholder approval for the cancellation of these shares [5][8]. Summary by Sections 1. Share Repurchase Plan Overview - In 2021, the company approved a share repurchase plan to buy back shares for employee stock ownership, with a maximum price of RMB 35 per share and a total fund of between RMB 30 million and RMB 50 million [1][2]. - By November 1, 2022, the company repurchased 18,273,500 shares, accounting for 0.9653% of the total share capital, with a total expenditure of RMB 355.78 million [2]. 2. Changes in Repurchase Plan - The company decided to terminate the 2022 restricted stock incentive plan due to unmet performance targets and stock price fluctuations [3]. - In 2023, a new repurchase plan was approved with a maximum price of RMB 25 per share and a total fund of between RMB 25 million and RMB 50 million [4]. 3. Change of Purpose for Repurchased Shares - The company intends to change the purpose of 37,215,700 repurchased shares to reduce registered capital, which will require shareholder approval [5][8]. - After the cancellation, the total share capital will decrease from 1,880,611,391 shares to 1,843,395,691 shares [5][7]. 4. Impact of Share Cancellation - The cancellation of repurchased shares is expected to enhance financial metrics such as earnings per share and net asset value without adversely affecting the company's operations or shareholder interests [8]. 5. Approval Process - The board of directors and the supervisory board have both approved the proposal to change the purpose of the repurchased shares and will seek shareholder approval for the necessary amendments to the company's articles of association [9].

Group 1 - The company plans to repurchase and cancel 302,600 restricted stocks and 164,000 stock options due to one incentive object failing to meet personal performance assessments in the 2023 and 2025 incentive plans [1][2] - The first exercise conditions for the 2024 stock option and restricted stock incentive plan have been met, allowing 13 incentive objects to exercise a total of 345,000 stock options [2] - The second unlock condition for the 2023 restricted stock incentive plan has been achieved, allowing 38 incentive objects to unlock and circulate 1,336,440 restricted stocks, which accounts for 0.14% of the company's total share capital [3]

Core Viewpoint - The company held its 10th board meeting on August 22, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and plans for stock options and share repurchase [1][2][3]. Group 1: Meeting Resolutions - The board approved the 2025 semi-annual report and summary, which was recognized by the audit committee prior to submission [1]. - A special report on the status of the company's fundraising and actual usage was also approved, following the audit committee's review [2]. - The board approved a proposal to grant reserved stock options to the incentive objects of the 2025 stock option incentive plan, which had been reviewed by independent directors and relevant committees [2]. - The board approved a share repurchase plan using self-owned funds through centralized bidding, aimed at enhancing the long-term incentive mechanism and employee motivation [2].

Core Viewpoint - The company has approved the cancellation of 1.255 million stock options granted to 9 departing incentive recipients, which will not impact the company's operational performance or management diligence [1][4]. Summary by Sections Stock Incentive Plan Overview - The company held meetings to discuss and approve the stock incentive plan, including the cancellation of stock options for departing employees [1][2]. Cancellation Reasons and Quantity - The cancellation involves 1.255 million stock options due to the departure of 9 incentive recipients who no longer qualify for the incentive program [4]. Impact of Cancellation on the Company - The cancellation of stock options will not affect the company's operational performance or the diligence of the management team [4]. Supervisory Board Opinion - The supervisory board confirmed that the cancellation process complies with relevant regulations and the company's incentive plan, deeming it legal and effective [4]. Legal Opinions - The legal firm provided an opinion stating that the cancellation of stock options has received necessary approvals and complies with relevant laws and regulations, affirming that it will not impact the company's performance [4].

证券代码：002293 证券简称：罗莱生活 公告编号:2025-035 罗莱生活科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 罗莱生活科技股份有限公司（以下简称"公司"或"罗莱生活"）于2025 年8月21日召开了第六届董事会第十五次会议与第六届监事会第十三次会议，审 议通过了《关于回购注销部分限制性股票的议案》，同意对2名离职的激励对象 已获授但尚未解除限售的25万股限制性股票予以回购注销，该议案尚需提交公司 一、股权激励计划简述 《关于 <公司 ensp="ensp" 年限制性股票与股票期权激励计划="年限制性股票与股票期权激励计划" 草案 ="草案"> 及其摘要的议案》 《关于 <公司 ensp="ensp" 年限制性股票与股票期权激励计划实施考核管理办法="年限制性股票与股票 期权激励计划实施考核管理办法"> 的议案》 及《关于核实公司<2024 年限制性股票与股票期权激励计划首次授予激励对象名 单>的议案》，同意公司实施本次激励计划。 票期权激励计划首次授予激励对象名单，对本次拟激励对象姓名及职务予以公示， 公示时间为 2024 ...

恒生电子股份有限公司 恒生电子股份有限公司 监事会关于公司 2022 年股票期权激励计划第三个行权期行权条件未 成就及注销部分已授予股票期权的核查意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 股权激励管理办法》等法律、法规以及《恒生电子股份有限公司章程》的规定， 恒生电子股份有限公司（以下简称"公司"）监事会就公司2022年股票期权激励 计划（以下简称"激励计划"）第三个行权期行权条件未成就及注销部分已授予 股票期权事项进行了核查，发表意见如下： 一、根据激励计划规定的行权条件，公司 2024 年业绩未达到激励计划规定的 公司层面业绩考核条件，公司 2022 年股票期权激励计划第三个行权期行权条件 未成就，该行权期激励对象对应考核当年可行权的股票期权不得行权，均由公司 注销。该行权期拟注销的股份数量为 633.848 万份。 二、鉴于原激励对象中 5 人因离职或职务变更而不再具备激励对象资格，监 事会同意取消上述激励对象资格并注销其已获授但尚未行权的股票期权合计 公司拟注销因上述原因不得行权的股票期权合计 646.6547 万份。本次注销 符合《上市公司股权激励管理办法》《2022 ...

Summary of the News Article Core Viewpoint The article discusses Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s plan to adopt a restricted share unit scheme for H shares in 2025, aimed at enhancing corporate governance and retaining talent through equity incentives. Group 1: Overview of the Plan - The company plans to implement a 2025 H share restricted share unit scheme to improve corporate governance and establish a long-term incentive mechanism [3][8]. - The total number of restricted share units to be granted under this plan is 13,370,500, which represents approximately 0.5007% of the company's total shares [2][8]. - The initial grant will consist of 10,696,400 restricted share units, accounting for 80% of the total plan [2][8]. Group 2: Details of the Initial Grant - The initial grant will be awarded to 201 eligible employees at a price of RMB 1.00 per unit after the units vest [2][6]. - The total number of shares available for the initial grant represents about 0.4005% of the company's total shares [2][8]. - The plan requires approval from the company's shareholders and the shareholders of its indirect controlling shareholder, Fosun International Limited, before implementation [3][7]. Group 3: Eligibility and Conditions - Eligible employees include executive directors, employee directors, senior management, and other key personnel deemed necessary for motivation [9]. - The plan's effectiveness is contingent upon shareholder approval and compliance with relevant laws and regulations [8][9]. - The vesting schedule for the initial grant is structured over three years, with 33% vesting after 12 months, another 33% after 24 months, and the final 34% after 36 months [17][18]. Group 4: Performance Assessment - The performance assessment for the group will focus on two key indicators: net profit attributable to shareholders and revenue from innovative drugs [20][21]. - The targets for these indicators are set for the upcoming years, with specific financial goals outlined for each assessment period [21][22]. - If the performance metrics are not met, the corresponding restricted share units may not vest [24].

Core Points - The company has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and retain talent [9][10][12] - The total number of stock options to be granted is capped at 5,726,100, representing approximately 0.2144% of the company's total shares [14][15] - The plan includes an initial grant of 4,580,900 options (80% of the total) and a reserved grant of 1,145,200 options (20% of the total) [15][24] Summary by Sections Purpose of the Plan - The plan aims to align the interests of shareholders, the company, and its core team, ensuring long-term development and motivation for key personnel [9][10] Management Structure - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [10][11] Incentive Recipients - The plan targets executive directors, employee directors, senior management, and other key employees, with a maximum of 201 initial recipients [12][13] Source and Quantity of Shares - The shares for the stock options will come from shares repurchased from the secondary market, with specific limits on the total number of shares that can be granted [14][15] Grant and Exercise Conditions - The exercise price for the initial grant is set at 27.93 yuan per share, based on the average trading price prior to the announcement [19][20] - The plan stipulates performance-based conditions for exercising options, including group-level financial metrics [21][24] Lock-up Regulations - There are restrictions on the transfer of shares by directors and senior management during their tenure and for a period after leaving the company [19][24]

Core Viewpoint - The company is implementing an A-share option incentive plan aimed at enhancing corporate governance, attracting and retaining talent, and aligning the interests of shareholders, the company, and its core team for long-term development [3][4]. Group 1: Company Overview - Fosun Pharma was listed on the Shanghai Stock Exchange on August 7, 1998, and on the Hong Kong Stock Exchange on October 30, 2012 [2]. - As of August 22, 2025, the total share capital of the company is 2,670,429,325 shares, comprising 2,118,488,825 A-shares and 551,940,500 H-shares [2]. - The company operates in the fields of biochemical products, reagents, and related consulting services, among others [2]. Group 2: Incentive Plan Details - The total number of A-share options to be granted under the plan is capped at 5,726,100, which corresponds to 0.2144% of the company's total shares [4][5]. - The initial grant will consist of 4,580,900 options (80% of the total), while 1,145,200 options (20%) will be reserved for future grants [5][6]. - The A-share options will be sourced from shares repurchased from the secondary market [4][6]. Group 3: Objectives and Benefits - The plan aims to improve corporate governance and establish a long-term incentive mechanism to motivate executives and employees [3][4]. - It seeks to align the interests of shareholders, the company, and its core team, fostering a collective focus on the company's long-term growth [3][4]. Group 4: Grant and Exercise Conditions - The exercise price for the initial grant of A-share options is set at 27.93 yuan per share, based on the average trading price prior to the announcement [10]. - The plan includes a waiting period before options can be exercised, with specific timelines for different tranches of options [11][12]. - The plan stipulates that the options can only be exercised if certain financial performance criteria are met, including net profit and revenue from innovative drugs [14][15]. Group 5: Financial Impact and Accounting - The total estimated expense for the initial grant of 4,580,900 A-share options is projected to be 12.14 million yuan, which will be amortized over the plan's duration [30][31]. - The plan's implementation is expected to have a positive impact on the company's performance, potentially outweighing the associated costs [31].

Core Viewpoint - The company announced the cancellation of a portion of stock options from its 2024 stock option incentive plan due to unmet performance conditions during the first exercise period, totaling 11.12 million options [1][2][3]. Group 1: Stock Option Incentive Plan - The board of directors approved the cancellation of stock options as the performance conditions for the first exercise period were not met, resulting in the cancellation of 9.7797 million options [1]. - An additional 1.112 million options were canceled due to 54 individuals no longer qualifying as incentive targets due to resignation or position changes [1]. - The total number of stock options canceled from the 2024 plan is 11.1232 million [1]. Group 2: Compliance and Approval - The cancellation process was conducted in accordance with the relevant regulations and does not require further shareholder approval, as it falls within the authorized scope of the board [1]. - The remuneration and assessment committee of the board confirmed that the cancellation aligns with regulatory requirements and will not adversely affect the company's stock distribution or the continuation of the incentive plan [1]. - The supervisory board also agreed that the cancellation complies with regulations and does not harm the interests of the company or its shareholders [1]. Group 3: Legal Opinion - The legal firm provided a conclusive opinion stating that the cancellation has received the necessary approvals and is in compliance with the relevant regulations [1].